NASDAQ:ERAS Erasca Q3 2025 Earnings Report $11.24 -0.36 (-3.10%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$11.31 +0.07 (+0.63%) As of 05/22/2026 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Erasca EPS ResultsActual EPS-$0.11Consensus EPS -$0.11Beat/MissMet ExpectationsOne Year Ago EPSN/AErasca Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AErasca Announcement DetailsQuarterQ3 2025Date11/12/2025TimeBefore Market OpensConference Call DateWednesday, November 12, 2025Conference Call Time4:00PM ETUpcoming EarningsErasca's Q2 2026 earnings is estimated for Tuesday, August 11, 2026, based on past reporting schedules, with a conference call scheduled on Monday, August 10, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsEarnings Release(8-K)Quarterly Report(10-Q) Erasca Earnings HeadlinesINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Erasca, Inc. - ERASMay 21 at 3:45 PM | prnewswire.comErasca, Inc. (ERAS) Shares Crater 48%, Wiping Out $2.8 Billion of Market Cap; Hagens Berman Investigating Intellectual Property Questions Regarding Lead AssetMay 21 at 9:00 AM | prnewswire.comSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a $1.75 trillion IPO - larger than Saudi Aramco and any tech offering in history. CNBC calls it 'the big market event of 2026.' According to former tech executive and angel investor Jeff Brown, there's a way to claim a stake before the public filing drops, starting with as little as $500.May 23 at 1:00 AM | Brownstone Research (Ad)ERAS INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Erasca, Inc.May 19, 2026 | businesswire.comERASCA INVESTOR ALERT: Bragar Eagel & Squire, P.C. is Investigating Erasca, Inc. on Behalf of Erasca Stockholders and Encourages Investors to Contact the FirmMay 19, 2026 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Erasca, Inc. - ERASMay 19, 2026 | globenewswire.comSee More Erasca Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Erasca? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Erasca and other key companies, straight to your email. Email Address About ErascaErasca (NASDAQ:ERAS) is a clinical‐stage biopharmaceutical company dedicated to the discovery and development of precision medicines for patients with cancer. The company focuses on small molecule therapeutics that target critical signaling pathways involved in tumor growth and survival, with a primary emphasis on inhibitors of the MAPK pathway. Erasca’s approach is designed to deliver oral, targeted therapies that address both oncogene‐driven and immuno‐oncology indications, aiming to improve outcomes for patients with unmet medical needs. Erasca’s pipeline comprises multiple development candidates, including small molecule inhibitors engineered to disrupt key nodes in cancer cell signaling. Among these are selective RAF dimer inhibitors and pan‐RAF inhibitors, which are being evaluated in various solid tumors harboring KRAS and BRAF mutations. The company employs a translational research strategy that integrates preclinical modeling, biomarker identification and early clinical proof‐of‐concept studies, enabling efficient progression of assets from the lab to first‐in‐human trials. Headquartered in San Diego, California, Erasca conducts its research and development activities in collaboration with leading academic institutions and clinical sites across North America and Europe. By leveraging a global network of investigators and trial centers, the company advances its candidates through multi‐site clinical studies, gathering data on safety, pharmacokinetics and preliminary efficacy in diverse patient populations. Founded in 2016, Erasca is led by Jack Bailey, Chief Executive Officer, who brings more than two decades of experience in oncology research and drug development. The company’s leadership team combines expertise in medicinal chemistry, translational biology and clinical operations, positioning Erasca to advance its mission of delivering innovative cancer therapies to patients worldwide.View Erasca ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Was Decker’s Double Beat a Bullish Signal—Or Mere HOKA’s-Pocus?Workday Validates AI Flywheel: Stock Price Recovery BeginsOverextended, e.l.f. Beauty Is Primed to Rebound in Back HalfDeere Beats Q2 Estimates, But Ag Weakness Weighs on OutlookNVIDIA Price Pullback? Don’t Count on It, Business Is AcceleratingMeta Platforms 10% Layoff Raises a Bigger Question About AI SpendingBiogen Stock Slides After Trial Miss, But Analysts Stay Bullish Upcoming Earnings AutoZone (5/26/2026)Marvell Technology (5/27/2026)PDD (5/27/2026)Synopsys (5/27/2026)Bank Of Montreal (5/27/2026)Bank of Nova Scotia (5/27/2026)Salesforce (5/27/2026)Snowflake (5/27/2026)Autodesk (5/28/2026)Costco Wholesale (5/28/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
